BRAF V600E inhibitors show improved outcomes in relapsed/refractory hairy cell leukemia.
Avani Yenamandra, PharmD, BCOP
Advertisement
Articles by Avani Yenamandra, PharmD, BCOP
Second-line and later treatment options for small cell lung cancer are limited.
These combination therapies have demonstrated longer PFS with a tolerable AE profile.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Evolving Strategies for RSV Prevention in Infants
2
Etentamig Shows Manageable Safety and Low Severe Infection Risk in RRMM
3
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis
4
Fun Fact: Researchers Crack the Myth of High Cholesterol and Eggs
5
